

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

---

**Ziopharm Oncology, Inc.**

(Name of issuer)

---

**Common Stock, par value \$0.001 per share**  
(Title of class of securities)

**98973P101**  
(CUSIP number)

**June 9, 2010**  
(Date of event which requires filing of this statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No. **98973P101**

1) Name of reporting persons  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)

**Abu Dhabi Investment Authority**

2) Check the appropriate box if a member of a group (see instructions)  
(a)  (b)

3) SEC use only

4) Citizenship or place of organization

**The Emirate of Abu Dhabi, United Arab Emirates**

5) Sole voting power

**0**

6) Shared voting power

**1,320,004<sup>(1)</sup>**

7) Sole dispositive power

**0**

8) Shared dispositive power

**1,320,004<sup>(1)</sup>**

9) Aggregate amount beneficially owned by each reporting person

**1,320,004<sup>(1)</sup>**10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) 

11) Percent of class represented by amount in Row (9)

**3.16%<sup>(2)</sup>**

12) Type of reporting person (see instructions)

**OO**

CUSIP No. <b>98973P101</b>	
1)	Name of reporting persons I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)  <b>Procific<sup>(3)</sup></b> <b>EIN # 98-0476810</b>
2)	Check the appropriate box if a member of a group (see instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3)	SEC use only
4)	Citizenship or place of organization  <b>Cayman Islands, British West Indies</b>
Number of shares beneficially owned by each reporting person with	5) Sole voting power  <b>0</b>
	6) Shared voting power  <b>1,320,004<sup>(1)</sup></b>
	7) Sole dispositive power  <b>0</b>
	8) Shared dispositive power  <b>1,320,004<sup>(1)</sup></b>
9)	Aggregate amount beneficially owned by each reporting person  <b>1,320,004<sup>(1)</sup></b>
10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions) <input type="checkbox"/>
11)	Percent of class represented by amount in Row (9)  <b>3.16%<sup>(2)</sup></b>
12)	Type of reporting person (see instructions)  <b>CO</b>

(1) Consists of 996,030 shares of common stock and 323,974 shares of common stock issuable pursuant to a warrant that is currently exercisable.

(2) 41,836,655 shares of common stock currently outstanding as reported in the Issuer's Prospectus on Form 424B5 filed with the Securities and Exchange Commission on May 27, 2010.

- (3) Procific is the actual owner of the shares of common stock and the shares of common stock underlying the warrants reported herein. Procific is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the Securities and Exchange Commission, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of common stock and the shares of common stock underlying the warrants actually owned by Procific.

SCHEDULE 13G

- Item 1**
- (a) Name of Issuer:  
Ziopharm Oncology, Inc.
- (b) Address of Issuer's Principal Executive Offices:  
1180 Avenue of the Americas  
19<sup>th</sup> Floor  
New York, New York 10036
- Item 2**
- (a) Name of Person Filing:
1. Abu Dhabi Investment Authority
  2. Procific
- (b) Address of Principal Business Office or, if none, Residence:
1. P.O. Box 3600  
Abu Dhabi, United Arab Emirates
  2. P.O. Box 7106  
Abu Dhabi, United Arab Emirates
- (c) Citizenship:
1. Abu Dhabi Investment Authority is an instrumentality of the Government of the Emirate of Abu Dhabi.
  2. Procific is a corporation organized under the laws of the Cayman Islands, British West Indies.
- (d) Title of Class of Securities:  
Common stock, par value \$0.001 per share
- (e) CUSIP Number:  
98973P101

**Item 3 Check appropriate box if this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c):**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with § 240.13d-1(b)(1)(ii)(J)

**Item 4 Ownership:**

(a) Amount beneficially owned:

See Item 9 of the cover page.

(b) Percent of class:

See Item 11 of the cover page.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

See Items 5-8 of the cover page.

**Item 5 Ownership of Five Percent or Less of a Class:**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6 Ownership of More Than Five Percent on Behalf of Another Person:**

Not Applicable.

**Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:**

Not Applicable.

**Item 8 Identification and Classification of Members of the Group:**

Not Applicable.

**Item 9 Notice of Dissolution of Group:**

Not Applicable.

**Item 10 Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

Date: June 17, 2010

**ABU DHABI INVESTMENT AUTHORITY**

/s/ HAREB AL DARMAKI

---

By: Hareb Al Darmaki

Title: Executive Director

/s/ KHALAF AL NAJJAS

---

By: Khalaf Al Najjas

Title: Assistant Director

**PROCIFIC**

/s/ AHMED GHUBASH

---

By: Ahmed Ghubash

Title: Director

**JOINT FILING AGREEMENT**

The undersigned hereby agree that the Statement on Schedule 13G filed herewith is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(k)(1)(iii) promulgated pursuant to the Securities Exchange Act of 1934, as amended, on behalf of each such person.

Date: June 17, 2010

**ABU DHABI INVESTMENT AUTHORITY**

/s/ HAREB AL DARMAKI

By: Hareb Al Darmaki

Title: Executive Director

/s/ KHALAF AL NAJJAS

By: Khalaf Al Najjas

Title: Assistant Director

**PROCIFIC**

/s/ AHMED GHUBASH

By: Ahmed Ghubash

Title: Director